Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

to $1.00 per share which may be paid upon the achievement of certain regulatory and commercial milestones. The first CVR payment of $0.50 per share (or $87.5 million) would become payable when either (i) Cinryze is approved by the FDA for acute treatment of HAE and the FDA grants orphan exclusivity for Cinryze encompassing the acute treatment of HAE to the exclusion of all other human C1 inhibitor products or, (ii) orphan exclusivity for the acute treatment of HAE has not become effective for any third party's human C1 inhibitor product by October 21, 2010. The second CVR payment of $0.50 per share ($87.5 million) would become payable when Cinryze reaches at least $600 million in cumulative net product sales within 10 years of closing of the acquisition.

Looking ahead in 2009

ViroPharma is providing guidance for the year 2009 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2009, ViroPharma expects the following

  • Net product sales are expected to be $250 to $270 million. This guidance assumes no generic versions of Vancocin are approved in 2009 and excludes any revenue guidance for Cinryze.

  • Research and development (R&D) and selling, general and administrative (SG&A) expenses, including the impact of SFAS 123R, are expected to be $130 to $145 million, which includes approximately $25 million of expenses and previous commitments related to maribavir. SFAS 123R expenses are expected to be between $11 and $13 million.

Conference Call and Webca
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 /PRNewswire/ ... en 1974, a été depuis ... compléter les évaluations cliniques traditionnelles par des ... Outcomes) et sur les impacts économiques des ... A cours d,une ...
(Date:9/18/2014)... September 18, 2014 SeqLL Inc., ... (tSMS™) technology, announced today the closing of a ... led by Genomic Diagnostic Technologies, will increase the ... applications. , Founded in March 2013 by Daniel ... Analyst at Helicos BioSciences, SeqLL has continued to ...
(Date:9/18/2014)... loss and diabetes prevention, could actually hasten the development ... it in a surprising way: by changing the composition ... population of bacteria residing in our intestines. These findings, ... published today in Nature . Among other things, ... Department, who led this research together with Prof. Eran ...
(Date:9/18/2014)... memory device for computing may have just taken an ... New York led by chemist Stephen O,Brien have discovered ... properties. , Combining both properties is very exciting scientifically ... for the devices that might ultimately be designed, in ... a single material, however, has proved difficult until now. ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Oxides discovered by CCNY team could advance memory devices 2
... 2012  The Angel Investor Management (AIM) Group announced today the ... the capital needs of entrepreneurs and investors in a seven-county ... bringing together a single network of angel investor groups in ... the economies of scale will work to benefit all," said ...
... 2012  Accelerate Brain Cancer Cure (ABC2) and ... medical centers to accelerate clinical validation of Exosome,s ... in brain cancer.  The collaboration ... biofluid-based diagnostic technology for early identification, progression ...
... CENTERVILLE, Mass., Feb. 6, 2012 UV Flu Technologies, Inc. ... to announce it is ahead of schedule in its continuing program ... Asher Enterprises, LLC, that the remaining and final convertible note, in ... "The progress we have made in the last twelve ...
Cached Biology Technology:Statewide Network of Angel Investor Groups Announced in Alabama 2Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer 2Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer 3Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer 4UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 2UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 3
(Date:9/18/2014)... Washington State University researchers have developed a unique method ... waste cleanup in rural areas. , The first ... inexpensive and quick way to clean up waste from ... reducing pollution. , Professor Haluk Beyenal and graduate ... and Architecture discuss the system in the online edition ...
(Date:9/18/2014)... Colo., USA A new GSA Bulletin ... the lower Rio Puerco and Chaco Wash in northern ... rings from salt cedar and willow, investigators were able ... or greater. They then combined this data with aerial ... the history of these arroyos. , Arroyos are deep, ...
(Date:9/18/2014)... BUFFALO, N.Y. A sleep-promoting circuit located deep in ... deep sleep. Discovered by researchers at Harvard School of ... and Biomedical Sciences, this is only the second "sleep ... to be both necessary and sufficient to produce deep ... Neuroscience , the study demonstrates that fully half of ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... the Smithsonian Institution (US), Saint Louis University ... the discovery of an exciting new species from the daisy family. ... Andes were crowned by the discovery of the beautiful and extraordinary, ... the open access journal Phytokeys . The ...
... University of Iowa have created a bio patch to ... a nano-sized particle that delivers bone-producing instructions directly into ... platform seeded with particles containing the genes needed for ... regrew bone fully enough to cover skull wounds in ...
... legislation "have eviscerated" the ability to protect habitat ... at the University of Calgary and Dalhousie University ... were "politically motivated," unsupported by scientific advice ... with ecosystem-based management, fisheries biologists John Post and ...
Cached Biology News:Crown of Venezuelan paramos: A new species from the daisy family, Coespeletia palustris 2A bio patch that can regrow bone 2A bio patch that can regrow bone 3Changes to fisheries legislation have removed habitat protection for most fish species in Canada 2
... The BD FACSVantageTM SE flow cytometry ... the research laboratory. For over 25 years, ... standard and are found in leading university, ... world. To meet the research demands ...
... ST-195 allows real-time observations of cell cultures ... has 64 different strain parameters in addition ... thin silicon strain chamber used by the ... fluorescence microscopy. ST-195 can be used with ...
... package is used for determining protein concentration in ... RC DC protein assay is a colorimetric assay. ... assays: 250 ml RC reagent I, 250 ml ... solution, 2 L dilute Folin reagent, and 5 ...
... Protein Precipitation Kit is designed for ... from aqueous samples. Proteomics sample analysis ... of non-protein impurities such as buffers, ... sample that interfere with electrophoretic separations ...
Biology Products: